Open AccessMelphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAMDex) Therapy for Multiple Myeloma
Author(s) -
D. Peest,
H. Deicher,
R. Coldewey,
von Broen Im,
Ursula Cammerer,
Reinhard Hein,
Lone Hoffmann,
H Konyar,
Kreuser Ed,
Johannes Selbach
Publication year - 1990
Publication title -
oncology research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.553
H-Index - 48
eISSN - 2296-5262
pISSN - 2296-5270
DOI - 10.1159/000216718
Subject(s) - melphalan , medicine , dexamethasone , prednisone , vincristine , multiple myeloma , chemotherapy , oncology , urology , cyclophosphamide
136 untreated multiple myeloma patients of stage II and III were collected in the study. 37/51 stage II patients had progressive disease and were treated with melphalan and prednisone (MP). 85 patients were of stage III and randomized into MP and vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) treatment groups. 55% of MP treated patients responded versus 75% of the VBAMDex group. Since the study has been activated only 16 months ago, no difference in survival could be observed.